Angiogenesis in malignancy

Seminars in Cancer Biology

Volumn 19, Issue 5, 2009, Pages 277-278

  Cao, Yihai ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOSTATIN; BEVACIZUMAB; ENDOSTATIN; PEGAPTANIB; PLATELET DERIVED GROWTH FACTOR B; SCATTER FACTOR; SOMATOMEDIN; SORAFENIB; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN INHIBITOR;

CANCER INVASION; CANCER RESEARCH; CANCER SURVIVAL; DISEASE MODEL; DRUG TARGETING; EDITORIAL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; METASTASIS POTENTIAL; NONHUMAN; PREDICTION; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 70450267621     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2009.11.001     Document Type: Editorial

References (27)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 21 (1971) 1182-1186
2. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., and Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 2 (1994) 315-328
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42.
4. Mayer R.J. Two steps forward in the treatment of colorectal cancer. N Engl J Med 350 23 (2004) 2406-2408
5. Sharieff W. Bevacizumab in colorectal cancer. N Engl J Med 351 16 (2004) 1690-1691 author reply 1690-1
6. Sonpavde G. Bevacizumab in colorectal cancer. N Engl J Med 351 16 (2004) 1690-1691 author reply 1690-1
7. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., Feinsod M., and Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 27 (2004) 2805-2816
8. Kerbel R.S. Tumor angiogenesis. N Engl J Med 358 19 (2008) 2039-2049
9. Cao Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv Cancer Res 100 (2008) 113-131
10. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23(31):8033-40.
11. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26(20):3403-10.
12. Bergers G., and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8 8 (2008) 592-603
13. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., and Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 3 (2009) 232-239
14. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., and Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 3 (2009) 220-231
15. Loupakis F., Falcone A., Masi G., Fioravanti A., Kerbel R.S., Del Tacca M., and Bocci G. Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol 25 13 (2007) 1816-1818
16. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116(10):2610-21.
17. Xue Y, Religa P, Cao R, Hansen AJ, Lucchini F, Jones B, et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci USA 2008;105(47):18513-8.
18. Ledford H. Drug markers questioned. Nature 452 7187 (2008) 510-511
19. Bjorndahl M.A., Cao R., Burton J.B., Brakenhielm E., Religa P., Galter D., Wu L., and Cao Y. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res 65 20 (2005) 9261-9268
20. Cao R, Bjorndahl MA, Religa P, Clasper S, Garvin S, Galter D, et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004;6(4):333-45.
21. Bjorndahl M., Cao R., Nissen L.J., Clasper S., Johnson L.A., Xue Y., et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci USA 102 43 (2005) 15593-15598
22. Cao R., Bjorndahl M.A., Gallego M.I., Chen S., Religa P., Hansen A.J., et al. Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. Blood 107 9 (2006) 3531-3536
23. Jiang W.G., Davies G., Martin T.A., Parr C., Watkins G., Mansel R.E., et al. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med 16 4 (2005) 723-728
24. Kajiya K., Hirakawa S., Ma B., Drinnenberg I., and Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J 24 16 (2005) 2885-2895
25. Morisada T, Oike Y, Yamada Y, Urano T, Akao M, Kubota Y, et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 2005;105(12):4649-56.
26. Partanen T.A., and Paavonen K. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc Res Tech 55 2 (2001) 108-121
27. Veikkola T., and Alitalo K. Dual role of Ang2 in postnatal angiogenesis and lymphangiogenesis. Dev Cell 3 3 (2002) 302-304